Tvardi Therapeutics, Inc. (TVRD): M&A transaction — Tvardi Q1 2025 net loss $9.6M, cash burn $7.7M; going concern doubt persists

Tvardi Therapeutics, Inc.

Net loss $9.6M ($0.50 dil EPS) vs $4.2M loss in Q1 2024; accumulated deficit $101.8M.
Revenue nil; operating expenses $4.35M (R&D $3.1M, G&A $1.2M).
Cash & equivalents $11.4M, short-term investments $10.9M at March 31; cash used in ops $7.7M.
Convertible notes $35.8M; other expense $5.5M from fair value change on notes.
Merger closed April 15, 2025 provided $23.8M cash; substantial doubt about going concern pre-merger.

item 2.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Tvardi Therapeutics, Inc. underwent a change of control involving CT Convergence Merger Sub, Inc. (closed 2025-04-15).

Action: change of control
Counterparty: CT Convergence Merger Sub, Inc.
Closing: 2025-04-15

Exact text from the filing

the Company reported, among other events, the completion of the Merger pursuant to which CT Convergence Merger Sub, Inc. merged with and into Tvardi Operating Company, Inc. (f/k/a Tvardi Therapeutics, Inc.)

View on SEC.gov

Browse all m&a transactions →

Tvardi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-047844

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.